There’s a growing demand for lyophilised pharmaceutical products that are contributing to an increase in the adoption of
lyophilisation equipment and the need for lyophilised biopharmaceuticals and other formulations in the pharmaceutical industry. This is contributing to the projected rise in investment, currently dominated by North America, which is expected to reach $4.80 billion in 2020. This rate of growth is a result of new biologics and biosimilars, enhancing the need for
lyophilisation equipment and services.
The requirements governed by the FDA and International Society of Pharmaceutical Engineers (ISPE) focus on improving patient safety and product quality – supporting the adoption of lyophilisation in pharmaceutical manufacturing, with the necessity to lyophilise APIs and various formulations such as antibodies, antiviral drugs, insulin, biosimilars, injections and other therapeutic proteins.
Benefits of Attending
- This scientifically sound conference will focus on process formulation and optimisation for biologics and vaccines with a key focus on the development of lyophilisation and scale up
- All challenges in lyophilisation and freeze drying technology will be considered and case studies will reflect and address the implementation process
- It’s important to have an up-to-date perspective of the lyophilisation process as a whole and the application in formulating solid protein pharmaceuticals so this conference will review the challenges to enhance improvements
Plus An Interactive Post-Conference Workshop | Friday 1st May 2015
The application of QbD to Freeze-DryingWorkshop Leader: Kevin Ward, Director of Research & Development, Biopharma Technology Limited
8.30am – 12.30pm
Speakers
- Akhilesh Bhambhani, Principal Scientist, Novel Adjuvants, Formulations and Delivery Technologies, Merck & Co. Inc.
- Andrea Weiland-Waibel, Owner, Explicat Pharma GmbH
- Barry D Moore, CSO, Xstalbio Ltd
- Constantin Loghinov, Marketing Manager Global, One 2 One Hospira
- Geoff Smith, Reader Pharmaceutical Technologies, De Montfort University
- Graham Magill, Engineer I, Pharmaceutical Processing and Technology Development, Genentech, Inc.
- Jamie Tsung, Principal Scientist, Momenta Pharmaceuticals Inc
- Kevin Ward, Director of R&D, BioPharma Technology
- Lindsay Wegiel, Research Associate III, Baxter Pharmaceutical Solutions, LLC
- Paul Coiteux, Director of Technical Sales, SP Scientific
- Ronald Pate, Lyophilization Development Scientist, Patheon Pharmaceuticals Inc.
- Stuart Wang, Sr. Scientist, Biogen Idec
- Sune Andersen, Principal Scientist Drying Processes, Novo Nordisk A / S
- Swapnil Pansare, Associate Scientist - I, Formulation Sciences, MedImmune Inc
- Tara Scherder, Managing Director, Arlenda
- Tim Paymaster, President, Ellab Inc
- Todd Thompson, President, Millrock Technology, Inc.
- Tudor Arvinte, Professor University of Geneva, Chairman & CEO, Therapeomic Inc., University Of Geneva
- Vikram Sadineni, Senior Research Investigator, BMS
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDf under downloads at the right side of the page.
Venue
Renaissance Woodbridge Hotel
515 US Highway 1 South, 08830
Iselin, NJ, United States
Who Should Attend
Presidents, Chief Executive Officers, Vice Presidents, Chief Scientific Officers, Directors, Business Development Managers, and Principal Scientists of:
- Vaccine/antibody/cell manufacturing
- Bioprocess research and development
- Chemical Engineering
- Process implementation and process engineering
- Stability testing
- Sterile production
- Quality assurance and quality control
- Standardisation science
- Drug formulation
- Active pharmaceutical ingredients
- Pharmaceutical production
- Manufacturing and engineering
- Licensing
- Product development
- Outsourcing/contract manufacturing
- Dried technology
- Packaging and labelling
- Pilot plant operations
Venue
Renaissance Woodbridge Hotel515 US Highway 1 South
Iselin, New Jersey 08830
USA
